(19)
(11) EP 4 031 166 A1

(12)

(43) Date of publication:
27.07.2022 Bulletin 2022/30

(21) Application number: 20864518.4

(22) Date of filing: 18.09.2020
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
 C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2317/64; C07K 16/2896; C07K 2317/52; C07K 2317/732; C07K 2317/734; C07K 2317/72; A61K 2039/505; A61P 35/02
(86) International application number:
PCT/US2020/051663
(87) International publication number:
WO 2021/055876 (25.03.2021 Gazette 2021/12)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 18.09.2019 US 201962902380 P

(71) Applicant: Momenta Pharmaceuticals, Inc.
Titusville NJ 08560 (US)

(72) Inventors:
  • ORTIZ, Daniel
    Horsham, PA 19044 (US)
  • CHOUDHURY, Amit
    Horsham, PA 19044 (US)

(74) Representative: Mathys & Squire 
The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

   


(54) COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38